GlobeNewswire PharmaOriginal article
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
RegulatoryPositive
AI Analysis
Summary
NeuroThera Labs, a SciSparc subsidiary, is pursuing FDA Orphan Drug Designation for an adult Tourette Syndrome treatment and has engaged RK Strategies to strengthen its U.S. market position and visibility with federal stakeholders.
Outcome Details
Pursuing FDA Orphan Drug Designation
Importance:4/10
Sentiment:
0.30
orphan drug designationFDATourette Syndromegovernment affairssubsidiary
Related Companies
Read the original article
Published by GlobeNewswire Pharma on September 2, 2026 12:17 PM